The closing price of Emergent Biosolutions Inc (NYSE: EBS) was $3.26 for the day, down -4.40% from the previous closing price of $3.41. In other words, the price has decreased by -$0.1500 from its previous closing price. On the day, 3217352 shares were traded.
Ratios:
Our analysis of EBS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.54 and its Current Ratio is at 1.07. In the meantime, Its Debt-to-Equity ratio is 1.26 whereas as Long-Term Debt/Eq ratio is at 0.66.
The Benchmark Company Upgraded its Hold to Buy on April 10, 2023, while the target price for the stock was maintained at $22.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 02 ’23 when Zoon Kathryn C sold 1,830 shares for $8.35 per share. The transaction valued at 15,280 led to the insider holds 49,971 shares of the business.
Zoon Kathryn C sold 1,700 shares of EBS for $14,246 on May 25 ’23. The Director now owns 51,801 shares after completing the transaction at $8.38 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EBS now has a Market Capitalization of 176.93M and an Enterprise Value of 950.93M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.15 while its Price-to-Book (P/B) ratio in mrq is 0.24. Its current Enterprise Value per Revenue stands at 0.88 whereas that against EBITDA is -1.79.
Stock Price History:
Over the past 52 weeks, EBS has reached a high of $13.67, while it has fallen to a 52-week low of $1.42. The 50-Day Moving Average of the stock is 2.1730, while the 200-Day Moving Average is calculated to be 4.2192.
Shares Statistics:
EBS traded an average of 2.98M shares per day over the past three months and 11.37M shares per day over the past ten days. A total of 50.10M shares are outstanding, with a floating share count of 49.75M. Insiders hold about 4.11% of the company’s shares, while institutions hold 79.36% stake in the company. Shares short for EBS as of Feb 15, 2024 were 11.54M with a Short Ratio of 3.87, compared to 11.82M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 22.23% and a Short% of Float of 36.82%.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of -$0.19 for the current quarter, with a high estimate of $0.07 and a low estimate of -$0.33, while EPS last year was -$0.31. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.03 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$4.67 and -$5.07 for the fiscal current year, implying an average EPS of -$4.87. EPS for the following year is $1.54, with 2 analysts recommending between $2.51 and $0.57.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $332.6M to a low estimate of $248M. As of the current estimate, Emergent Biosolutions Inc’s year-ago sales were $330.7M, an estimated decrease of -11.20% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $1.11B, while the lowest revenue estimate was $1.02B, resulting in an average revenue estimate of $1.07B. In the same quarter a year ago, actual revenue was $1.12B, down -4.80% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $1.18B in the next fiscal year. The high estimate is $1.19B and the low estimate is $1.17B. The average revenue growth estimate for next year is up 11.00% from the average revenue estimate for this year.
